{{Rsnum
|rsid=1045642
|Gene=ABCB1
|Chromosome=7
|position=87509329
|Orientation=minus
|ReferenceAllele=T
|GMAF=0.3967
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=ABCB1
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 15.0 | 55.8 | 29.2
| HCB | 40.0 | 45.2 | 14.8
| JPT | 28.3 | 53.1 | 18.6
| YRI | 80.0 | 18.6 | 1.4
| ASW | 62.5 | 33.9 | 3.6
| CHB | 40.0 | 45.2 | 14.8
| CHD | 35.2 | 55.6 | 9.3
| GIH | 17.8 | 47.5 | 34.7
| LWK | 0.0 | 0.0 | 0.0
| MEX | 25.9 | 56.9 | 17.2
| MKK | 72.1 | 26.0 | 1.9
| TSI | 30.4 | 46.1 | 23.5
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs1045642
|Name_s=ABCB1:3435C>T
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=Web Resource:http://www.pharmgkb.org/search/annotatedGene/abcb1/variant.jsp#ImportantVariantInformationforABCB1-3435
|Annotation=This SNP is well-studied but there is no clear consensus on its significance for drug disposition, response or toxicity.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=In-Depth
|PharmGKB Accession ID=PA161145208
}}{{PharmGKB
|RSID=rs1045642
|Name_s=ABCB1:C3435T
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=PubMed ID:17185560
|Annotation=rs1045642 is associated with altered inhibition by verapamil and cyclosporin A of substrate uptake in vitro.
|Drugs=cyclosporine; verapamil
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA161868039
}}{{PharmGKB
|RSID=rs1045642
|Name_s=ABCB1: 3435C>T
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=PubMed ID:12082591
|Annotation=Individuals that are homozygotes for 3435T alleles of ABCB1 have increased risk of developing nortriptyline-induced postural hypotension.This variant is also associated with expression level and in vivo function of ABCB1.
|Drugs=nortriptyline
|Drug Classes=
|Diseases=Depression; Depressive Disorder; Depressive Disorder, Major; Hypotension
|Curation Level=Curated
|PharmGKB Accession ID=PA162290073
}}{{PharmGKB
|RSID=rs1045642
|Name_s=ABCB1:3435C>T
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=PubMed ID:12082591
|Annotation=The T allele of this SNP is associated with nortriptyline-induced postural hypotension in patients treated for major depression. This SNP is not associated with response to treatment with nortriptyline or fluoxetine.
|Drugs=nortriptyline
|Drug Classes=
|Diseases=Hypotension, Orthostatic
|Curation Level=Curated
|PharmGKB Accession ID=PA162355845
}}{{PharmGKB
|RSID=rs1045642
|Name_s=ABCB1:C3435T, MDR1:C3435T
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=PubMed ID:19093297
|Annotation=Indian rheumatoid arthritis patients heterozygous for this SNP (CT genotype) had about double the risk of non-response to methotrexate.
|Drugs=methotrexate
|Drug Classes=
|Diseases=Arthritis, Rheumatoid
|Curation Level=Curated
|PharmGKB Accession ID=PA162363714
}}{{PharmGKB
|RSID=rs1045642
|Name_s=ABCB1:3435C>T, MDR1 3435C>T
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=PubMed ID:16912956
|Annotation=Decreased risk of hepatotoxicity was associated with ABCB1:3435C>T in a study of HIV patients receiving either efavirenz- or nevirapine-containing drug regimens.
|Drugs=efavirenz; nevirapine
|Drug Classes=
|Diseases=HIV
|Curation Level=Curated
|PharmGKB Accession ID=PA162928798
}}{{PharmGKB
|RSID=rs1045642
|Name_s=ABCB1:3435C>T, MDR1 3435C>T
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=PubMed ID:16912957
|Annotation=In a study of HIV patients in South Africa, participants who experienced hepatotoxicity were less likely to have at least one T allele of the variant ABCB1:3435C>T.
|Drugs=efavirenz
|Drug Classes=
|Diseases=HIV
|Curation Level=Curated
|PharmGKB Accession ID=PA162928797
}}{{PharmGKB
|RSID=rs1045642
|Name_s=ABCB1: C3435T
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=PubMed ID:17112805; PubMed ID:19106083
|Annotation=The C3435T variant (rs1045642) at exon 26 in the ABCB1 was showed to influence clopidogrel absorption in patients with a cardiovascular disease. Plasma concentrations of clopidogrel and its active metabolite were reduced in patients carrying the TT genotype.
|Drugs=clopidogrel
|Drug Classes=
|Diseases=Cardiovascular Diseases
|Curation Level=Curated
|PharmGKB Accession ID=PA162372986
}}{{PharmGKB
|RSID=rs1045642
|Name_s=ABCB1:3435C>T
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=PubMed ID:17190370
|Annotation=(R)-lansoprazole concentrations significantly increased in CYP2C19 extensive metabolizers with the ABCB1 C3435T C allele, but not TT genotype, after renal transplantation and treatment with tacrolimus and lansoprazole.
|Drugs=lansoprazole; tacrolimus
|Drug Classes=
|Diseases=Gastroesophageal Reflux; Transplantation
|Curation Level=Curated
|PharmGKB Accession ID=PA162652705
}}{{PharmGKB
|RSID=rs1045642
|Name_s=ABCB1:3435 C>T
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=PubMed ID:16950614
|Annotation=Patients with both rs1045642 and rs2032582 variants have been associated with neutropenia from paclitaxel.
|Drugs=paclitaxel
|Drug Classes=
|Diseases=Neutropenia
|Curation Level=Curated
|PharmGKB Accession ID=PA164920327
}}{{PharmGKB
|RSID=rs1045642
|Name_s=ABCB1:3435 C>T
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=PubMed ID:18836089
|Annotation=Patients with this variant with metastatic breast cancer treated with palitaxel showed a significantly lower disease control rate and lower overall survival rate than the CC variant allele.
|Drugs=paclitaxel
|Drug Classes=
|Diseases=Breast Neoplasms
|Curation Level=Curated
|PharmGKB Accession ID=PA164920323
}}{{PharmGKB
|RSID=rs1045642
|Name_s=ABCB1:3435C>T; MDR1 C3435T
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=PubMed ID:19752884
|Annotation=In Slovak (White) breast cancer patients (n=221) receiving anthracycline-based chemotherapy, the CC genotype of ABCB1:3435C>T was associated with longer time to progression.
|Drugs=doxorubicin; epirubicin
|Drug Classes=
|Diseases=Breast Neoplasms
|Curation Level=Curated
|PharmGKB Accession ID=PA165107206
}}{{PharmGKB
|RSID=rs1045642
|Name_s=ABCB1:3435T>C, Ile1145Ile
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=PubMed ID:12352921; Web Resource:http://www.pharmgkb.org/search/annotatedGene/abcb1/variant.jsp#ImportantVariantInformationforABCB1-3435
|Annotation=Risk or phenotype-associated allele: T allele. Phenotype: Decreased drug-induced neurotoxicity (e.g. convulsion, tremor, leukoencephalopathy) in recipients of liver transplantation associated with the T allele in combination with other factors (e.g. ABCB1:2677G>T/A, tacrolimus trough concentration, aspartate aminotransferase, ratio of graft weight-to-recipient's standard liver volume). Study size: 17 (6 with and 11 without neurotoxicity). Study population/ethnicity: Liver transplant patients from Kyushu University Hospital in Japan. Significance metric(s): chi-squared = 7.91; p < 0.005. Type of association: GN; PK; PD; TOX; ADR.
|Drugs=tacrolimus
|Drug Classes=
|Diseases=Drug Toxicity; liver transplantation
|Curation Level=In-Depth
|PharmGKB Accession ID=PA164946503
}}{{PharmGKB
|RSID=rs1045642
|Name_s=PGP C3435T; ABCB1:3435C>T
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=PubMed ID:17038883
|Annotation=Risk or phenotype-associated allele: T. Phenotype: In subjects carrying one or two T alleles of this variant, the plasma olanzapine level alone was positively associated with percent change in Brief Psychiatric Rating Scale (BPRS) score. As olanzapine plasma levels increased, the BPRS score increased. Study size: 41. Study population/ethnicity: Patients with schizophrenia; > 90% Caucasian. Significance metric(s): p = 0.02. Type of association: CO.
|Drugs=olanzapine
|Drug Classes=
|Diseases=Schizophrenia
|Curation Level=Curated
|PharmGKB Accession ID=PA165108055
}}{{PharmGKB
|RSID=rs1045642
|Name_s=ABCB1:3435C>T, mRNA 3853C>T, p.Ile1145Ile
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=PubMed ID:16331627
|Annotation=Clinical outcome and P-gp activity was studied in Asian patients with de novo acute myeloid leukemia taking cytarabine and idarubicin, relative to ABCB1 genotypes, C3435T (rs1045642) and G2677T/A (rs2032582, Ala893Ser/Thr). Three-year event-free survival (EFS) was higher in 2677 GG homozygotes (893Ala/Ala) (60.6%) versus non-GG genotypes (893Ser allele-harboring subjects) (21.9%; p = 0.02), and in 3435 CC homozygotes versus non-CC genotypes (p = 0.01), and for 2677GG (893Ala/Ala)/3435CC diplotypes (58.2%) versus other diplotypes (22.6%; p = 0.04); although no significant genotypic or haplotypic association was observed for overall survival (OS). The rate of complete remission was significantly higher in 3435 CC (p = 0.05) and 2677 GG (893Ala/Ala) (p = 0.04) homozygotes, and for the 3435CC/2677GG diplotype (p = 0.03) compared to non-GC haplotype homozygotes. Using an in vitro daunorubicin accumulation assay with leukemic mononuclear cells from AML patients, 3435 CC homozygotes showed significantly lower P-gp activity (7.5%) than for CT (10.7%) and TT (19.9%) genotypes (p = 0.029); and G2677T/A (Ala893Ser/Thr) genotype had no effect (p = 0.181).
|Drugs=cytarabine; idarubicin
|Drug Classes=
|Diseases=Leukemia, Myeloid, Acute
|Curation Level=Curated
|PharmGKB Accession ID=PA164953199
}}{{PharmGKB
|RSID=rs1045642
|Name_s=ABCB1:3435C>T, mRNA 3853C>T, Ile1145Ile
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=PubMed ID:11503014
|Annotation=3435TT homozygotes showed statistically different fenofexadine area under the concentration curve (AUC) values for 0-4 hours (p = 0.036) than CC homozygotes.
|Drugs=fexofenadine
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA164944054
}}{{PharmGKB
|RSID=rs1045642
|Name_s=ABCB1:3435C>T, mRNA 3853C>T, Ile1145Ile
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=PubMed ID:17206635
|Annotation=There was no significant association between the genotype C3435T distribution and the risk of Cyclosporin A failure in steroid resistance ulcerative colitis (p = 0.23).
|Drugs=cyclosporine
|Drug Classes=
|Diseases=Colitis, Ulcerative
|Curation Level=Curated
|PharmGKB Accession ID=PA164953179
}}{{PharmGKB
|RSID=rs1045642
|Name_s=ABCB1:3435T>C, Ile1145Ile
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=PubMed ID:14711599
|Annotation=Risk or phenotype-associated allele: none. Phenotype: Efavirenz and lopinavir plasma levels. Study size: 67. Study population/ethnicity: HIV patients. Significance metric(s): not available from abstract. Type of association: GN; PK.
|Drugs=efavirenz; lopinavir
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165291614
}}{{PharmGKB
|RSID=rs1045642
|Name_s=ABCB1:3435T>C, Ile1145Ile
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=PubMed ID:15452306
|Annotation=Risk or phenotype-associated allele: TT gentoype and T allele. Phenotype: Risk of antiepileptic drug resistance (refractory epilepsy) is not associated with the 3435 SNP, although the T allele (p = 0.013) and TT gentoype (OR = 2.67; p = 0.026) were associated with temporal lobe epilepsy (TLE) with hippocampal sclerosis (HS) compared to TLE without HS in a subgroup. Study size: 609 (401 drug-resistant and 208 drug-responsive); 226 TLE subgroup (116 with HS, 110 without HS). Study population/ethnicity: Ethnically-matched drug-resistant and drug-responsive epilepsy patients. Significance metric(s): p = 0.013 (allelic); OR = 2.67, p = 0.026 (genotypic). Type of association: GN; CO.
|Drugs=
|Drug Classes=
|Diseases=Drug Resistance; Epilepsy
|Curation Level=Curated
|PharmGKB Accession ID=PA165291617
}}{{PharmGKB
|RSID=rs1045642
|Name_s=ABCB1:3435T>C, Ile1145Ile
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=PubMed ID:15280437
|Annotation=Risk or phenotype-associated allele: TT genotype. Phenotype: Decreased ABCB1 (P-gp) expression in placenta and liver. Study size: 115 (96 placental and 19 liver tissue samples). Study population/ethnicity: Japanese. Significance metric(s): p < 0.05. Type of association: GN; FA.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165291616
}}{{PharmGKB
|RSID=rs1045642
|Name_s=ABCB1:3435T>C, Ile1145Ile
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=PubMed ID:14747421
|Annotation=Risk or phenotype-associated allele: CC genotype. Phenotype: CC genotype associated with decreased tacrolimus levels after 1 and 3 months (p < 0.05), but no genotypic association at 6, 9, and 12 months (p > 0.05) post-transplantation immunosuppressive therapy. Study size: 83. Study population/ethnicity: Adult lung transplant recipients, from the USA. Significance metric(s): p < 0.05 (1, 3 months Tx); p > 0.05 (6, 9, 12 months Tx). Type of association: GN; PK.
|Drugs=tacrolimus
|Drug Classes=
|Diseases=Transplantation
|Curation Level=Curated
|PharmGKB Accession ID=PA165291615
}}{{PharmGKB
|RSID=rs1045642
|Name_s=ABCB1:3435C>T
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=PubMed ID:18377430
|Annotation=Risk or phenotype-associated allele: T. Phenotype: A haplotype of ABCB1 c.1236C>T, c.2677G>A/T, and c.3435C>T (rs1128503, rs2032582 and rs1045642) was associated with increased drug exposure and reduced clearance. Study size: . Study population/ethnicity: Asian patients with Breast Neoplasms treated with doxorubicin. Significance metric(s): p = 0.03 (exposure); p= 0.01 (clearance). Type of association: PK.
|Drugs=doxorubicin
|Drug Classes=
|Diseases=Breast Neoplasms
|Curation Level=Curated
|PharmGKB Accession ID=PA165291811
}}{{PharmGKB
|RSID=rs1045642
|Name_s=
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=PubMed ID:20801498
|Annotation=Risk or phenotype-associated genotype: CC. Phenotype: In patients with or without ST-elevation acute coronary syndrome a higher rate of of ischaemic events were observed for patients with the ABCB1 3435 CC genotype (high-expression group) than for those with polymorphisms of intermediate (CT) or low expression (TT) who were on clopidogrel. Study size: 5148 patients receiving 75 mg clopidogrel once daily Study population/ethnicity: predominantly white (98%) Type of association: GN
|Drugs=clopidogrel
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165374698
}}{{PharmGKB
|RSID=rs1045642
|Name_s=ABCB1: c.3435C>T, mRNA 3853C>T
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=PubMed ID:12781336
|Annotation=Functional study of rs1045642 (3435C>T) and rs1128503 (2677G>T/A): in LLC-PK1 cells expressing wild-type (2677G/3435C) or polymorphic (2677G/3435T, 2677A/3435C, 2677A/3435T, 2677T/3435C, 2677T/3435T) constructs of ABCB1 in vitro, no significant differences were observed in transcellular efflux of structurally diverse P-gp substrates, verapamil, digoxin, vinblastine or cyclosporin A.
|Drugs=cyclosporine; digoxin; verapamil; vinblastine
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165110268
}}{{PharmGKB
|RSID=rs1045642
|Name_s=ABCB1: c.3435C>T, mRNA 3853C>T, p.Ile1145Ile
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=PubMed ID:12781336
|Annotation=Functional study of rs1045642 (3435C>T) and rs2032582 (2677G>T/A): in LLC-PK1 cells expressing wild-type (2677G/3435C) or polymorphic (2677G/3435T, 2677A/3435C, 2677A/3435T, 2677T/3435C, 2677T/3435T) constructs of ABCB1 in vitro, no significant differences were observed in transcellular efflux of structurally diverse P-gp substrates, verapamil, digoxin, vinblastine or cyclosporin A.
|Drugs=cyclosporine; digoxin; verapamil; vinblastine
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165110368
}}{{PharmGKB
|RSID=rs1045642
|Name_s=ABCB1: c.3435C>T, mRNA 3853C>T
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=PubMed ID:15521904
|Annotation=Haplotypes derived from the SNPs 2677G > T (rs2032582) and 3435C > T (rs1045642) do not influence the pharmacokinetics of tacrolimus in renal transplant patients
|Drugs=tacrolimus
|Drug Classes=
|Diseases=Transplantation
|Curation Level=Curated
|PharmGKB Accession ID=PA165110372
}}{{PharmGKB
|RSID=rs1045642
|Name_s=ABCB1: c.3435C>T, mRNA 3853C>T, p.Ile1145Ile
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=PubMed ID:14600574
|Annotation=No significant association between allelic ABCB1 variants, C3435T (rs1045642) and G2677T/A (Ala893Ser) (rs2032582), and phase 1 or phase 2 viral decay, changes in lymphocyte subsets over time, or plasma trough ritonavir concentrations among 31 HIV-infected individuals initiating antiretroviral therapy.
|Drugs=ritonavir
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165110370
}}{{PharmGKB
|RSID=rs1045642
|Name_s=ABCB1:3435C>T, mRNA 3853C>T, Ile1145Ile
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=PubMed ID:18851956
|Annotation=Risk or phenotype-associated allele: 3435 CT and TT genotypes. Phenotype: ABCB1 polymorphisms were associated with risk for coronary artery disease (CAD) (p<0.05). Carriers of 3435 CT and TT genotypes (63%) and 2677 non-GG (non 893Ala/Ala) genotypes (64%) had higher frequency of family history of coronary artery disease (CAD) than the 3435CC (44%, p = 0.042) and 2677GG (46%, p = 0.043) carriers. The frequency of CAD in those carrying the 3435/2677 T/T haplotype (67%) was higher than that found in 3435/2677 non-T/T individuals (47%, p = 0.021). ABCB1 substrates (antiarrhythmics, beta-blockers, diuretics, ACE inhibitors, and others) or inhibitors (antiarrhythmics, calcium antagonists, calcium channel blockers, antidepressants and others) did not affect the baseline ABCB1 expression, but ABCB1 inhibitors reversed the effects of atorvastatin on both ABCB1 and ABCC1 transporters. Study size: 136. Study population/ethnicity: Hypercholesterolemic individuals, treated with atorvastatin (10mg/day/4 weeks), evaluated for CAD risk factors at the Institute Dante Pazzanese of Cardiology and the Hospital of the Sao Paulo University in Sao Paulo City, Brazil. Significance metric(s): p < 0.05. Type of association: GN; PD; FA
|Drugs=atorvastatin
|Drug Classes=
|Diseases=Coronary Artery Disease; Hypercholesterolemia
|Curation Level=Curated
|PharmGKB Accession ID=PA165110749
}}{{PharmGKB
|RSID=rs1045642
|Name_s=ABCB1: c.3435C>T, mRNA 3853C>T, p.Ile1145Ile; ABCB1*6
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=PubMed ID:15122075
|Annotation=Risk or phenotype-associated allele: none. Phenotype: There was no significant association between systemic exposure of tipifarnib (AUC levels) and rs1045642 genotype. Study size: 28 (16 male). Study population/ethnicity: Caucasian cancer patients, aged 34-75. Significance metric(s): Not significant, p = 0.92. Type of association: GN; PK
|Drugs=Tipifarnib
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165111311
}}{{PharmGKB
|RSID=rs1045642
|Name_s=ABCB1:3435T>C, Ile1145Ile
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=PubMed ID:11809184
|Annotation=Risk or phenotype-associated allele: TT allele. Phenotype: Increased efavirenz and nelfinavir response after 6 months treatment. Study size: 123. Study population/ethnicity: White HIV patients. Significance metric(s): p = 0.0001. Type of association: GN; PD.
|Drugs=efavirenz; nelfinavir
|Drug Classes=
|Diseases=HIV
|Curation Level=Curated
|PharmGKB Accession ID=PA165291600
}}{{PharmGKB
|RSID=rs1045642
|Name_s=ABCB1:3435C>T, mRNA 3853C>T, Ile1145Ile
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=PubMed ID:12781336
|Annotation=Risk or phenotype-associated allele: None. Phenotype: Efflux of P-glycoprotein substrates (verapamil; digoxin; vinblastine; cyclosporin A) in vitro were not significantly affected by combined mutations for rs1128503 (2677G>T/A) and rs1045642 (3435C>T) in LLC-PK1 cell lines. Study size: Triplicate cell assays. Study population/ethnicity: N/A. Significance metric(s): Not significant, p > 0.05. Type of association: FA
|Drugs=cyclosporine; digoxin; verapamil; vinblastine
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165110748
}}{{PharmGKB
|RSID=rs1045642
|Name_s=c.3435C>T
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=PubMed ID:20017669
|Annotation=Risk or phenotype-associated allele: C. Phenotype: This variant is associated with nevirapine-induced hepatotoxicity in patients from Mozambique, with the T allele showing a protective effect. Study size: 156 (78 with nevirapine-induced hepatotoxicity and 78 without adverse events). Study population/ethnicity: HIV infected patients from Mozambique. Significance metric(s): p = 0.038; odds ratio: 0.42. Type of association: GN; CO
|Drugs=nevirapine
|Drug Classes=
|Diseases=Drug Toxicity; HIV Infections
|Curation Level=Curated
|PharmGKB Accession ID=PA165111621
}}{{PharmGKB
|RSID=rs1045642
|Name_s=ABCB1:3435T>C, Ile1145Ile
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=PubMed ID:11434506
|Annotation=Risk or phenotype-associated allele: TT genotype. Phenotype: Decreased ABCB1 (P-gp) expression in leukocytes isolated from subjects, and increased in vitro rhodamine exposure in peripheral blood cells isolated from subjects. Study size: 31. Study population/ethnicity: Caucasians from Germany. Significance metric(s): p < 0.01. Type of association: GN; FA.
|Drugs=rhodamine 123
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165291599
}}{{PharmGKB
|RSID=rs1045642
|Name_s=ABCB1:3435T>C, Ile1145Ile
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=PubMed ID:10716719
|Annotation=Risk or phenotype-associated allele: TT genotype. Phenotype: Decreased expression of intestinal ABCB1 (P-gp) (p = 0.056, n = 21), and increased plasma levels of digoxin relative to the CC genotype (p = 0.006, n = 14). Study size: 21 duodenum samples, and 14 PK subjects. Study population/ethnicity: Caucasians from Germany. Significance metric(s): p = 0.006 - 0.056. Type of association: GN; PK; FA.
|Drugs=digoxin
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165291598
}}{{PharmGKB
|RSID=rs1045642
|Name_s=ABCB1:3435T>C, Ile1145Ile
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=PubMed ID:15778422
|Annotation=Risk or phenotype-associated allele: none. Phenotype: No genetic association with dicloxacillin pharmacokinetics given 1g dicloxacillin prior to or after 600 mg rifampin (ABCB1 (P-gp) inducer). Study size: 18 (13 male). Study population/ethnicity: Healthy volunteers (12 Caucasian, 5 Asian, 1 African American, 1 subject undetermined) from San Francisco, California, USA. Significance metric(s): not significant. Type of association: GN; PK.
|Drugs=dicloxacillin; rifampin
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165291619
}}{{PharmGKB
|RSID=rs1045642
|Name_s=ABCB1:3435T>C, Ile1145Ile
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=PubMed ID:12492608; Web Resource:http://www.pharmgkb.org/search/annotatedGene/abcb1/variant.jsp#ImportantVariantInformationforABCB1-3435
|Annotation=Risk or phenotype-associated allele: none. Phenotype: No association with digoxin disposition (AUC, C(max), T(max)) after a single oral dose. Study size: 50. Study population/ethnicity: Healthy, unrelated, white male non-smokers, aged 18-40, from Berlin, Germany. Significance metric(s): p >= 0.3. Type of association: GN; PK.
|Drugs=digoxin
|Drug Classes=
|Diseases=
|Curation Level=In-Depth
|PharmGKB Accession ID=PA165291623
}}{{PharmGKB
|RSID=rs1045642
|Name_s=ABCB1:3435T>C, Ile1145Ile
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=PubMed ID:12175731; Web Resource:http://www.pharmgkb.org/search/annotatedGene/abcb1/variant.jsp#ImportantVariantInformationforABCB1-3435
|Annotation=Risk or phenotype-associated allele: CC genotype. Phenotype: Increased time to wean from steroid treatment in pediatric heart transplantation. Study size: 69. Study population/ethnicity: Pediatric heart transplant patients from the Children's Hospital of Pittsburgh, Pennsylvania, USA. Significance metric(s): p = 0.04. Type of association: GN; PD.
|Drugs=prednisone
|Drug Classes=
|Diseases=Drug Resistance; Organ Transplantation
|Curation Level=In-Depth
|PharmGKB Accession ID=PA165291622
}}{{PharmGKB
|RSID=rs1045642
|Name_s=ABCB1:3435T>C, Ile1145Ile
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=PubMed ID:12686700; Web Resource:http://www.pharmgkb.org/search/annotatedGene/abcb1/variant.jsp#ImportantVariantInformationforABCB1-3435
|Annotation=Risk or phenotype-associated allele: CC genotype. Phenotype: Increased antiepileptic drug resistance. Study size: 315 (200 drug-resistant, 115 drug-responsive). Study population/ethnicity: Epilepsy patients from England, classified as drug-resistant or drug-responsive. Significance metric(s): OR = 2.66; p = 0.006. Type of association: GN; PD.
|Drugs=
|Drug Classes=
|Diseases=Drug Resistance; Epilepsy
|Curation Level=In-Depth
|PharmGKB Accession ID=PA165291625
}}{{PharmGKB
|RSID=rs1045642
|Name_s=ABCB1:3435T>C, Ile1145Ile
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=PubMed ID:12684679; Web Resource:http://www.pharmgkb.org/search/annotatedGene/abcb1/variant.jsp#ImportantVariantInformationforABCB1-3435
|Annotation=Risk or phenotype-associated allele: TT genotype. Phenotype: Increased drug response to anthracyclines and taxanes in breast cancer. Study size: 68. Study population/ethnicity: Locally advanced stage breast cancer patients undergoing preoperative chemotherapy. Significance metric(s): p = 0.029. Type of association: GN; PD.
|Drugs=
|Drug Classes=ANTHRACYCLINES AND RELATED SUBSTANCES; TAXANES
|Diseases=Breast Neoplasms
|Curation Level=In-Depth
|PharmGKB Accession ID=PA165291624
}}{{PharmGKB
|RSID=rs1045642
|Name_s=ABCB1:3435T>C, Ile1145Ile
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=PubMed ID:12969965; Web Resource:http://www.pharmgkb.org/search/annotatedGene/abcb1/variant.jsp#ImportantVariantInformationforABCB1-3435
|Annotation=Risk or phenotype-associated allele: CC genotype. Phenotype: Increased etoposide clearance. Study size: 109 (104 whites, 42 blacks). Study population/ethnicity: Black and white children, newly diagnosed with acute lymphoblastic leukemia, from the USA. Significance metric(s): p = 0.027. Type of association: GN; PK.
|Drugs=etoposide
|Drug Classes=
|Diseases=Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=In-Depth
|PharmGKB Accession ID=PA165291627
}}{{PharmGKB
|RSID=rs1045642
|Name_s=ABCB1:3435T>C, Ile1145Ile
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=PubMed ID:12739761; Web Resource:http://www.pharmgkb.org/search/annotatedGene/abcb1/variant.jsp#ImportantVariantInformationforABCB1-3435
|Annotation=Risk or phenotype-associated allele: TT genotype. Phenotype: Decreased digoxin absorption after direct delivery to the surface of the duodenum by endoscope. Study size: 11 (5 CC genotype, 6 TT genotype). Study population/ethnicity: Unrelated, healthy subjects from Kobe, Japan. Significance metric(s): p = 0.007. Type of association: GN; PK.
|Drugs=digoxin
|Drug Classes=
|Diseases=
|Curation Level=In-Depth
|PharmGKB Accession ID=PA165291626
}}{{PharmGKB
|RSID=rs1045642
|Name_s=ABCB1:3435T>C, Ile1145Ile
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=PubMed ID:14586389; Web Resource:http://www.pharmgkb.org/search/annotatedGene/abcb1/variant.jsp#ImportantVariantInformationforABCB1-3435
|Annotation=Risk or phenotype-associated allele: none. Phenotype: No association with plasma levels after a single dose of loperamide, nor drug-induced respiratory depression (pharmacodynamic evidence of brain penetration as an unintended drug target). Study size: 16 (8 TT genotype, 8 CC genotype). Study population/ethnicity: Healthy Caucasians from San Francisco, California, USA. Significance metric(s): p > 0.05. Type of association: GN; PK; ADR.
|Drugs=loperamide
|Drug Classes=
|Diseases=
|Curation Level=In-Depth
|PharmGKB Accession ID=PA165291629
}}{{PharmGKB
|RSID=rs1045642
|Name_s=ABCB1:3435T>C, Ile1145Ile
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=PubMed ID:14583680; Web Resource:http://www.pharmgkb.org/search/annotatedGene/abcb1/variant.jsp#ImportantVariantInformationforABCB1-3435
|Annotation=Risk or phenotype-associated allele: TT genotype. Phenotype: Decreased tacrolimus levels in a subset of 29 post-operative kidney transplant patients (p < 0.01), and lower incidence of steroid-induced osteonecrosis in 136 patients (OR = 0.1; p = 0.034). Study size: 136 (30 osteonecrosis cases, 106 without osteonecrosis for 2 years post-transplant). Study population/ethnicity: Post-operative kidney transplant patients from Japan. Significance metric(s): OR = 0.10, p = 0.034 (osteonecrosis incidence); p < 0.01 (tacrolimus levels). Type of association: GN; PK; ADR.
|Drugs=tacrolimus
|Drug Classes=
|Diseases=Organ Transplantation
|Curation Level=In-Depth
|PharmGKB Accession ID=PA165291628
}}{{PharmGKB
|RSID=rs1045642
|Name_s=ABCB1:3435T>C, Ile1145Ile
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=PubMed ID:12142082; Web Resource:http://www.pharmgkb.org/search/annotatedGene/abcb1/variant.jsp#ImportantVariantInformationforABCB1-3435
|Annotation=Risk or phenotype-associated allele: TT genotype. Phenotype: Decreased or no ABCB1 (P-gp) expression in mammary and ovarian carcinoma cell lines. Study size: < 40. Study population/ethnicity: not stated. Significance metric(s): p = 0.0448. Type of association: GN; FA.
|Drugs=
|Drug Classes=
|Diseases=Carcinoma
|Curation Level=In-Depth
|PharmGKB Accession ID=PA165291621
}}{{PharmGKB
|RSID=rs1045642
|Name_s=ABCB1:3435T>C, Ile1145Ile
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=PubMed ID:11994059; Web Resource:http://www.pharmgkb.org/search/annotatedGene/abcb1/variant.jsp#ImportantVariantInformationforABCB1-3435
|Annotation=Risk or phenotype-associated allele: TT genotype. Phenotype: Increased cellular rhodamine levels in leukocytes isolated from subjects (p < 0.05), but no association with fexofenadine plasma levels in the subjects. Study size: 20. Study population/ethnicity: Caucasian volunteers from Germany. Significance metric(s): p < 0.05 Type of association: GN; PK; FA.
|Drugs=fexofenadine; rhodamine 123
|Drug Classes=
|Diseases=
|Curation Level=In-Depth
|PharmGKB Accession ID=PA165291620
}}{{PharmGKB
|RSID=rs1045642
|Name_s=ABCB1:3435T>C, Ile1145Ile
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=PubMed ID:16267764; Web Resource:http://www.pharmgkb.org/search/annotatedGene/abcb1/variant.jsp#ImportantVariantInformationforABCB1-3435
|Annotation=Risk or phenotype-associated allele: T allele, TT genotype. Phenotype: Association with decreased virologic failure (p = 0.05, TT vs. CC/CT), decreased drug resistance (OR = 0.56, p = 0.05), and increased toxicity-related treatment failure (p = 0.05) with efavirenz (EFV); however, no association with nelfinavir (NLF) or efavirenz response (e.g. increase in CD4 T cell count) (p > 0.1) nor nelfinavir or efavirenz exposure. Study size: 504 (340 efavirenz, 348 nelfinavir, 184 both drugs). Study population/ethnicity: Subset of larger study of 504 (49% whites, 31% blacks, 19% Hispanics from the USA and Italy) randomized antiretroviral-naive HIV-1 patients who were administered efavirenz plus two nucleoside analogues. Significance metric(s): p = 0.05 (ERV: less virologic failure, drug resistance, tox-related Tx failure); p > 0.1 (EFV/NLF response); not significant (EFV/NLF exposure). Type of association: GN; PK; PD; TOX; ADR.
|Drugs=efavirenz; nelfinavir
|Drug Classes=
|Diseases=HIV
|Curation Level=In-Depth
|PharmGKB Accession ID=PA165291630
}}{{PharmGKB
|RSID=rs1045642
|Name_s=ABCB1: 3435C>T
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=PubMed ID:20801494
|Annotation=Risk or phenotype-associated genotype: TT. Phenotype: ABCB1 3435C>T genotype was significantly associated with the risk of cardiovascular death, myocardial infarction, or stroke (p=0.0064). ABCB1 3435 TT homozygotes had a 72% increased risk of cardiovascular death, myocardial infarction, or stroke compared with CT/CC individuals HR 1.72, 95% CI 1.22-2.44, p=0.002). CT heterozygotes were at similar risk to CC individuals (HR 0.94, 0.58-1.51). Study size/population: 1471 patients with acute coronary syndromes taking clopidogrel. Type of association: CO; GN; ADR
|Drugs=clopidogrel
|Drug Classes=
|Diseases=Cardiovascular Diseases; Death, Sudden, Cardiac; Myocardial Infarction; Stroke
|Curation Level=Curated
|PharmGKB Accession ID=PA165374665
}}{{PharmGKB
|RSID=rs1045642
|Name_s=ABCB1:3435T>C, Ile1145Ile
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=PubMed ID:15778422
|Annotation=Risk or phenotype-associated allele: none. Phenotype: No association with dicloxacillan pharmacokinetics given 1g dicloxacillan prior to or after 600 mg rifampin (ABCB1 (P-gp) inducer). Study size: 18 (13 male). Study population/ethnicity: Healthy volunteers (12 Caucasian, 5 Asian, 1 African American, 1 subject undetermined) from San Francisco, California, USA. Significance metric(s): not significant. Type of association: GN; PK.
|Drugs=dicloxacillin; rifampin
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165292171
}}

{{omim
|desc=ATP-BINDING CASSETTE, SUBFAMILY B, MEMBER 1; ABCB1
|id=171050
|rsnum=1045642
|variant=0002
}}

{{PharmGKB
|RSID=rs1045642
|Name_s=ABCB1:3435C>T, mRNA 3853C>T, Ile1145Ile
|Gene_s=ABCB1
|Feature=Exon/Syn
|Evidence=PubMed ID:12914549
|Annotation=ABCB1 rs2032582 and rs1045642 genotype and peripheral blood lymphocyte efflux of P-gp substrate, rhodamine 123 (Rh123), in vitro, in healthy males: there was no significant difference in Rh123 efflux in CD56+ NK cells after 5, 10, 15, and 30 min efflux, or in CD4+ T-helper cells after 15, 30, 60, and 90 min between individuals with different genotypes. Rh123 efflux was not enhanced by a 10-day administration of P-gp inducer, rifampin, in vivo in 15 individuals before and after rifampin treatment. No genotypic effect was observed for inhibition of Rh123 efflux by P-pg inhibitor, verapamil, in vitro with CD56+ and CD4+.
|Drugs=rifampin; verapamil
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165110728
}}
[[rs1045642]], also known as C3435T, is a SNP located in the [[ABCB1]] gene. It is often studied in conjunction with [[rs2032582]]. C3435T has been mentioned by:

* {{PMID|17185560}} A "Silent" Polymorphism in the MDR1 Gene Changes Substrate Specificity (for example, to [[verapamil]])
* {{PMID|17190370}} (R)-[[lansoprazole]] ([[Prevacid]]) concentrations are significantly increased in [[CYP2C19]] extensive metabolizers with ABCB1 C3435T C allele.
* {{PMID|15536457}} In a Korean population, plasma concentrations of [[fexofenadine]] ([[Allegra]]) were 17% lower in 2677AA/3435CC subjects and 47% higher in the 2677TT/3435TT subjects compared to 2677GG/3435CC subjects.
* {{PMID|11994059|OA=1
}} In contrast, in this study no association was observed between the C3435T polymorphism and fexofenadine plasma or urine concentrations in a German Caucasian population.
* {{PMID|20491876}} A meta-analysis including 9 case-control studies (totaling ~2,500 patients) found no association between [[rs1045642]] and epilepsy risk

A study of 98 methadone-maintaining patients concluded that the higher (>150 mg/day) and lower (< or =150 mg/day) [[methadone]] dose groups differed significantly in their [[rs1128503]] status (experiment-wise p = 0.0325). Furthermore, individuals with the 3-locus genotype pattern (T;T)-(T;T)-(T;T) for SNPs [[rs1045642]], [[rs2032582]] and [[rs1128503]], respectively, had an approximately 5-fold chance of requiring the 'higher' methadone dose, while individuals heterozygous for these three SNPs have an approximately 3-fold chance of stabilizing at the 'lower' methadone dose (point-wise p-value = 0.026).{{PMID|18424454|OA=1
}}

{{PMID Auto
|PMID=19437139
|Title=ABCB1 single nucleotide polymorphisms in the Brazilian population
}}

{{PMID Auto
|PMID=20664232
|Title=Antidepressants and ABCB1 Gene C3435T Functional Polymorphism: A Naturalistic Study
}}

{{PMID Auto
|PMID=20944127
|Title=Two multidrug-resistance (ABCB1) gene polymorphisms as prognostic parameters in women with ovarian cancer
}}
{{PMID Auto
|PMID=21247447
|Title=CYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population
|OA=1
}}

{{omim
|id=171050
|rsnum=1045642
|variant=0002
}}

{{omim
|id=610064
|rsnum=1045642
}}

{{PMID Auto
|PMID=21902503
|Title=ABCB1 polymorphisms and neuropsychiatric adverse events in oseltamivir-treated children during influenza H1N1/09 pandemia
}}

{{PMID Auto
|PMID=22015057
|Title=Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study
}}

{{PMID Auto
|PMID=22110582
|Title=Association of MDR1 Gene SNPs and Haplotypes with the Tacrolimus Dose Requirements in Han Chinese Liver Transplant Recipients
|OA=1
}}

{{PMID Auto
|PMID=22120734
|Title=Identification of pharmacogenetic predictors of lipid-lowering response to atorvastatin in Chilean subjects with hypercholesterolemia
}}

{{PMID Auto
|PMID=21705081
|Title=Multidrug resistance gene expression and ABCB1 SNPs in plasma cell myeloma
}}

{{PMID Auto
|PMID=22176633
|Title=ABCB1/MDR1 polymorphism and colorectal cancer risk: a meta-analysis of case-control studies
}}

{{PMID Auto
|PMID=21806386
|Title=Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients
}}

{{PMID Auto
|PMID=22416375
|Title=[Genetic performance criteria valproate in patients with epilepsy]
}}

{{PMID Auto
|PMID=22630058
|Title=ABCC2 Polymorphisms and Haplotype are Associated with Drug Resistance in Chinese Epileptic Patients
}}

{{PMID|15197162|OA=1
}} Identifying candidate causal variants responsible for altered activity of the ABCB1 multidrug resistance gene.

{{PMID|15805193|OA=1
}} Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin.

{{PMID|16999857|OA=1
}} ABCB1 genotypes and haplotypes in patients with dementia and age-matched non-demented control patients.

{{PMID|17146660}} Association of MDR1 genotypes with susceptibility to colorectal cancer in older non-smokers.

{{PMID|17366837|OA=1
}} Genetic studies of a cluster of acute lymphoblastic leukemia cases in Churchill County, Nevada.

{{PMID|17548681}} MDR1 gene variants, indoor insecticide exposure, and the risk of childhood acute lymphoblastic leukemia.

{{PMID|17674045}} No association between MDR1 (ABCB1) 2677G>T and 3435C>T polymorphism and sporadic colorectal cancer among Bulgarian patients.

{{PMID|17913323}} ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder.

{{PMID|18182569|OA=1
}} Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology Group.

{{PMID|18213362|OA=1
}} Multiplexed genotyping of ABC transporter polymorphisms with the Bioplex suspension array.

{{PMID|18285546|OA=1
}} A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group.

{{PMID|18518969|OA=1
}} Association of ABCB1 genetic variants with renal function in Africans and in Caucasians.

{{PMID|18547414|OA=1
}} Genotyping panel for assessing response to cancer chemotherapy.

{{PMID|18698231|OA=1
}} Polymorphisms affecting gene transcription and mRNA processing in pharmacogenetic candidate genes: detection through allelic expression imbalance in human target tissues.

{{PMID|18725235|OA=1
}} Bidirectional translational research: Progress in understanding addictive diseases.

{{PMID|18784455|OA=1
}} The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis.

{{PMID|18812236}} No association of ABCB1 polymorphisms with drug-refractory epilepsy in a north Indian population.

{{PMID|18854777|OA=1
}} Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy.

{{PMID|18936436|OA=1
}} Prevalence in the United States of selected candidate gene variants: Third National Health and Nutrition Examination Survey, 1991-1994.

{{PMID|19155191|OA=1
}} Opiate and cocaine addiction: from bench to clinic and back to the bench.

{{PMID|19193698|OA=1
}} Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate.

{{PMID|19197249|OA=1
}} Steroid biosynthesis and renal excretion in human essential hypertension: association with blood pressure and endogenous ouabain.

{{PMID|19285141|OA=1
}} Genetic determinants of target and novelty-related event-related potentials in the auditory oddball response.

{{PMID|19373654}} ABCB1 (MDR1) rs1045642 is associated with increased overall survival in plasma cell myeloma.

{{PMID|19694740|OA=1
}} No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin.

{{PMID|19740399|OA=1
}} Influence of ABCB1 polymorphisms and haplotypes on tacrolimus nephrotoxicity and dosage requirements in children with liver transplant.

{{PMID|19930591|OA=1
}} Polymorphisms in the xenobiotic transporter Multidrug Resistance 1 (MDR1) and interaction with meat intake in relation to risk of colorectal cancer in a Danish prospective case-cohort study.

{{PMID|20170205}} Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.

{{PMID|20214406}} Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.

{{PMID|20354687|OA=1
}} Explaining variability in ciclosporin exposure in adult kidney transplant recipients.

{{PMID|20389299|OA=1
}} Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism.

{{PMID|20533057|OA=1
}} ABCB1/MDR1 gene polymorphisms as a prognostic factor in colorectal cancer.

{{PMID|20859246}} ABCB1 gene polymorphisms are associated with the severity of major depressive disorder and its response to escitalopram treatment.

{{PMID|21102498}} Cytochrome P450 genetic polymorphisms influence the serum concentration of calcineurin inhibitors in allogeneic hematopoietic SCT recipients.

{{PMID|21172166|OA=1
}} Pharmacogenetics of antidepressant response.

{{PMID|21185600}} Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia.

{{PMID|21332314}} Impact of ABCB1 C3435T polymorphism on lymph node regression in multimodality treatment of locally advanced esophageal cancer.

{{PMID|21364332}} Ultra-resistant schizophrenia is not associated with the multidrug-resistant transporter 1 (MDR1) gene rs1045642 variant.

{{PMID|21468756}} The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients.

{{PMID|21544031}} Expression of CYP3A5 and P-glycoprotein in renal allografts with histological signs of calcineurin inhibitor nephrotoxicity.

{{PMID|21553324}} Polymorphisms of the MDR1 and MIF genes in children with nephrotic syndrome.

{{PMID|21827404}} The clinical impact of ABCB1 polymorphisms on the treatment of psychiatric diseases.

{{PMID|21840870}} Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy.

{{PMID|21896346}} Polymorphisms in genes that regulate cyclosporine metabolism affect cyclosporine blood levels and clinical outcomes in patients who receive allogeneic hematopoietic stem cell transplantation.

{{PMID|22112610|OA=1
}} Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study.

{{PMID|22134106}} ABCB1 haplotype is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib.

{{PMID|22135187}} Variants in ABCB1, TGFB1, and XRCC1 genes and susceptibility to viral hepatitis A infection in Mexican Americans.

{{PMID|22136368}} Influence of genomic ancestry on the distribution of SLCO1B1, SLCO1B3 and ABCB1 gene polymorphisms among Brazilians.

{{PMID|22306099}} Association between the functional polymorphism (C3435T) of the gene encoding P-glycoprotein (ABCB1) and major depressive disorder in the Japanese population.

{{PMID|22311042}} MDR1 C3435T polymorphism and cancer risk: a meta-analysis based on 39 case-control studies.

{{PMID|22396794|OA=1
}} A comprehensive investigation on common polymorphisms in the MDR1/ABCB1 transporter gene and susceptibility to colorectal cancer.

{{PMID|22434582}} Neither P-gp SNP variants, P-gp expression nor functional P-gp activity predicts MDR in a preliminary study of plasma cell myeloma.

{{PMID|22569204|OA=1
}} PharmGKB summary: phenytoin pathway.

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1045642
|overall_frequency_n=6244
|overall_frequency_d=10758
|overall_frequency=0.580405
|n_genomes=46
|n_genomes_annotated=0
|n_haplomes=72
|n_articles=27
|n_articles_annotated=1
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=22672924
|Title=Polymorphisms of the drug transporter gene ABCB1 predict side effects of treatment with cabergoline in patients with PRL adenomas
}}

{{PMID Auto
|PMID=23188198
|Title=ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression
|OA=1
}}

{{PMID Auto
|PMID=23279665
|Title=ABCB1/MDR1 gene polymorphism and colorectal cancer risk: a meta-analysis of case-control studies
}}

{{PMID Auto
|PMID=22910404
|Title=Genetic association study of the P300 endophenotype in schizophrenia
}}

{{PMID Auto
|PMID=23546964
|Title=Frequency of MDR1 single nucleotide polymorphisms in a Jordanian population, including a novel variant
}}

{{PMID Auto
|PMID=23093106
|Title=Detection of frequent ABCB1 polymorphisms by high-resolution melting curve analysis and their effect on breast carcinoma prognosis
}}

{{PMID Auto
|PMID=23786015
|Title=[Pharmacogenetic criteria drug-resistence epilepsy]
}}

{{PMID Auto
|PMID=23803057
|Title=Gene Polymorphisms of OPRM1 A118G and ABCB1 C3435T May Influence Opioid Requirements in Chinese Patients with Cancer Pain
}}

{{PMID Auto
|PMID=23372834
|Title=ABCB1 variation and treatment response in AIDS patients: initial results of the Henan cohort
|OA=1
}}

{{PMID Auto
|PMID=23926124
|Title=A Functional Common Polymorphism of the ABCB1 Gene Is Associated With Chronic Kidney Disease and Hypertension in Chinese
}}

{{PMID Auto
|PMID=24070710
|Title=Association between MDR1 C3435T polymorphism and risk of breast cancer
}}

{{PMID Auto
|PMID=24086514
|Title=Association of Polymorphisms in Pharmacogenetic Candidate Genes (OPRD1, GAL, ABCB1, OPRM1) with Opioid Dependence in European Population: A Case-Control Study
|OA=1
}}

{{PMID Auto
|PMID=23917080
|Title=ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas
}}

{{PMID Auto
|PMID=24380367
|Title=Epigenetic modulation of the drug resistance genes MGMT, ABCB1 and ABCG2 in glioblastoma multiforme
|OA=1
}}

{{PMID Auto
|PMID=24469730
|Title=Genetic association of the P-glycoprotein gene ABCB1 polymorphisms with the risk for steroid-induced osteonecrosis of the femoral head in Chinese population
}}

{{PMID Auto
|PMID=24499375
|Title=Association of Oxidative Stress Related Genes with Idiopathic Recurrent Miscarriage
}}

{{PMID Auto
|PMID=24577069
|Title=Implication of P-Glycoprotein in Formation of Depression-Prone Personality: Association Study between the C3435T MDR1 Gene Polymorphism and Interpersonal Sensitivity
}}

{{PMID Auto
|PMID=22859359
|Title=ABCB1 and ABCC3 gene polymorphisms are associated with first-year response to methotrexate in juvenile idiopathic arthritis.
}}

{{PMID Auto
|PMID=22875622
|Title=Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy.
|OA=1
}}

{{PMID Auto
|PMID=23107763
|Title=Host genetic risk factors for community-acquired pneumonia.
}}

{{PMID Auto
|PMID=23133420
|Title=Pharmacogenomic Diversity among Brazilians: Influence of Ancestry, Self-Reported Color, and Geographical Origin.
|OA=1
}}

{{PMID Auto
|PMID=23133441
|Title=ABCB1 4036A>G and 1236C>T Polymorphisms Affect Plasma Efavirenz Levels in South African HIV/AIDS Patients.
|OA=1
}}

{{PMID Auto
|PMID=23443032
|Title=Fetal polymorphisms at the ABCB1-transporter gene locus are associated with susceptibility to non-syndromic oral cleft malformations.
}}

{{PMID Auto
|PMID=23504525
|Title=Association between the C3435T polymorphism of ABCB1/MDR1 gene (rs1045642) and colorectal cancer susceptibility : a meta-analysis based on 11,339 subjects.
}}

{{PMID Auto
|PMID=23647060
|Title=Candidate gene association studies and risk of chronic lymphocytic leukemia: a systematic review and meta-analysis.
}}

{{PMID Auto
|PMID=23733030
|Title=Pharmacogenetics in major depression: a comprehensive meta-analysis.
}}

{{PMID Auto
|PMID=23896815
|Title=Influence of ATP-binding cassette polymorphisms on neurological outcome after traumatic brain injury
}}

{{PMID Auto
|PMID=24915124
|Title=Common genetic variants in the glucocorticoid receptor and the 11β-Hydroxysteroid dehydrogenase type 1 genes influence long-term cognitive impairments in patients with Cushing's syndrome in remission
}}

{{PMID Auto
|PMID=24918524
|Title=Association study between the MDR1 gene and clinical characteristics in schizophrenia
}}

{{PMID Auto
|PMID=23996099
|Title=ABCB1 and ABCC1 variants associated with virological failure of first-line protease inhibitors antiretroviral regimens in Northeast Brazil patients
}}

{{PMID Auto
|PMID=25007187
|Title=Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia
}}

{{PMID Auto
|PMID=25217066
|Title=Relationship Between ABCB1 Polymorphisms, Thromboelastography and Risk of Bleeding Events in Clopidogrel-Treated Patients With ST-Elevation Myocardial Infarction
}}
{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}